Clinical Trial

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP)α in solid tumors, alone and in combination with pembrolizumab.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-10; most recent amendment 2026-01-15.
Status change: Recruiting → Active, Not Recruiting 2026-01-15
Status change: Not Yet Recruiting → Recruiting 2025-07-31
Trial Details
NCT Number NCT06932952
Lead Sponsor Byondis B.V.
Conditions Solid Tumor
Enrollment 7 participants
Start Date 2025-05-07
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-16